Miruna Micheu

Dr. Miruna Micheu

Clinical Emergency Hospital of Bucharest, Romania
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2019 in Medicina
Verified
Journal Article
Open access
PDF file
PNPopa- Fotea Nicoleta-Monica
Popa- Fotea Nicoleta-Monica
MMMiruna Micheu
Miruna Micheu
BVBataila Vlad
Bataila Vlad
ASAlexandru Scafa-Udriste
Alexandru Scafa-Udriste
LDLucian Florin Dorobanţu
Lucian Florin Dorobanţu
Maria DorobantuMaria Dorobantu
Maria Dorobantu
The concepts underlying hypertrophic cardiomyopathy (HCM) pathogenesis have evolved greatly over the last 60 years since the pioneering work of the British pathologist Donald Teare, presenting the autopsy findings of “asymmetric hypertrophy of the heart in young adults”. Advances in human genome analysis and cardiac imaging techniques have enriched our understanding of the complex architecture of the malady and shaped the way we perceive the illness continuum. Presently, HCM is acknowledged as “a disease of the sarcomere”, where the relationship between genotype and phenotype is not straightforward but subject to various genetic and nongenetic influences. The focus of this review is to discuss key aspects related to molecular mechanisms and imaging aspects that have prompted genotype–phenotype correlations, which will hopefully empower patient-tailored health interventions.

Verified
Journal Article
Open access
PDF file
ASAlina Scarlatescu
Alina Scarlatescu
MMMiruna Micheu
Miruna Micheu
PNPopa- Fotea Nicoleta-Monica
Popa- Fotea Nicoleta-Monica
Maria DorobantuMaria Dorobantu
Maria Dorobantu
Despite diagnostic and therapeutic advances, coronary artery disease and especially its extreme manifestation, ST elevation myocardial infarction (STEMI), remain the leading causes of morbidity and mortality worldwide. Early and prompt diagnosis is of great importance regarding the prognosis of STEMI patients. In recent years, microRNAs (miRNAs) have emerged as promising tools involved in many pathophysiological processes in various fields, including cardiovascular diseases. In acute coronary syndromes (ACS), circulating levels of miRNAs are significantly elevated, as an indicator of cardiac damage, making them a promising marker for early diagnosis of myocardial infarction. They also have prognostic value and great potential as therapeutic targets considering their key function in gene regulation. This review aims to summarize current information about miRNAs and their role as diagnostic, prognostic and therapeutic targets in STEMI patients.

23 February 2021 in Atmosphere
Verified
Journal Article
Open access
PDF file
BKBodor Katalin
Bodor Katalin
MMMiruna Micheu
Miruna Micheu
ÁKÁgnes Keresztesi
Ágnes Keresztesi
MBMarius-Victor Birsan
Marius-Victor Birsan
INIon-Andrei Nita
Ion-Andrei Nita
RSRóbert Szép
Róbert Szép
This study presents the PM10 concentration, respiratory and cardiovascular disease hospital admissions evolution in the Ciuc basin for a period of 9 years (2008–2016), taking into consideration different meteorological conditions: boundary layer, lifting condensation level, temperature-humidity index, and wind chill equivalent chart index. The PM10 and hospital admissions evolution showed a very fluctuated hourly, weekly, monthly, yearly tendency. The PM10 concentration in winter (34.72 μg/m3) was 82% higher than the multiannual average (19.00 μg/m3), and almost three times higher than in summer (11.71 μg/m3). During the winter, PM10 concentration increased by an average of 9.36 μg/m3 due to the increased household heating. Climatological parameters have a demonstrable effect on the PM10 concentration variation. Children, the elderly and men are more sensitive to air pollution, the calculated relative risk for men was (RR = 1.45), and for women (RR = 1.37), respectively. A moderate correlation (0.51) was found between PM10 and pneumonia (P), while a relatively weak correlation (0.39) was demonstrated in the case of PM10 and upper respiratory tract infections (URTI). Furthermore, except thermal humidity index (THI), strong negative correlations were observed between the multiannual monthly mean PM10 and the meteorological data. The PM10 followed a moderate negative correlation with the boundary layer (−0.61). In the case of URTI and P, the highest number of hospital admissions occurred with a 5 to 7-day lag, while the 10 μg/m3 PM10 increase resulted in a 2.04% and 8.28% morbidity increase. For lung cancer (LC) and cardiovascular diseases (AMI, IHD, CCP), a maximum delay of 5–6 months was found. Three-month delay and an average growth of 1.51% was observed in the case of chronic obstructive pulmonary disease (COPD). Overall, these findings revealed that PM10 was and it is responsible for one-third of the diseases.

12 August 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
ASAlina Scarlatescu
Alina Scarlatescu
Teodora BarbalataTeodora Barbalata
Teodora Barbalata
ASAnca V. Sima
Anca V. Sima
Camelia Sorina StancuCamelia Sorina Stancu
Camelia Sorina Stancu
Loredan Stefan NiculescuLoredan Stefan Niculescu
Loredan Stefan Niculescu
MMMiruna Micheu
Miruna Micheu
Acute ST elevation myocardial infarction (STEMI) remains a leading cause of morbidity and mortality worldwide despite continuous advances in diagnostic, prognostic and therapeutic methods. Myocardial work (MW) indices and miRNAs have both emerged as potential prognostic markers in acute coronary syndromes in recent years. In this study we aim to assess the prognostic role of myocardial work indices and of a group of miRNAs in young patients with STEMI. We enrolled 50 young patients (<55 years) with STEMI who underwent primary PCI and 10 healthy age-matched controls. We performed standard 2D and 3D echocardiography; we also calculated left ventricular global longitudinal strain (GLS) and the derived myocardial work indices. Using RT-PCR we determined the plasmatic levels of six miRNAs: miR-223-3p, miR-142-3p, miR-146a-5p, miR-125a-5p, miR-486-5p and miR-155-5p. We assessed the occurrence of major adverse cardiac events (MACE) at up to one year after STEMI. Out of 50 patients, 18% experienced MACE at the one-year follow-up. In a Cox univariate logistic regression analysis, myocardial work indices were all significantly associated with MACE. The ROC analysis showed that GWI, GCW and GWE as a group have a better predictive value for MACE than each separately (AUC 0.951, p = 0.000). Patients with higher miRNAs values at baseline (miR-223-3p, miR-142-3p and miR-146a-5p) appear to have a higher probability of developing adverse events at 12 months of follow-up. ROC curves outlined for each variable confirmed their good predictive value (AUC = 0.832, p = 0.002 for miR-223-3p; AUC = 0.732, p = 0.031 for miR-142-3p and AUC = 0.848, p = 0.001 for miR-146a-5p); the group of three miRNAs also proved to have a better predictive value for MACE together than separately (AUC = 0.862). Moreover, adding each of the miRNAs (miR-233, miR-142-3p and miR-146a-5p) or all together over the myocardial work indices in the regression models improved their prognostic value. In conclusion, both myocardial work indices (GWI, GCW and GWE) and three miRNAs (miR-223-3p, miR-142-3p and miR-146a-5p) have the potential to be used as prognostic markers for adverse events after acute myocardial infarction. The combination of miRNAs and MW indices (measured at baseline) rather than each separately has very good predictive value for MACE in young STEMI patients (C-statistic 0.977).

21 January 2022 in World Journal of Clinical Cases
Verified
Journal Article
Open access
IRIulia Rusu
Iulia Rusu
MTMalina Turlacu
Malina Turlacu
MMMiruna Micheu
Miruna Micheu
Severe acute respiratory syndrome coronavirus 2 infection affects not only the lungs, but also the cardiovascular system, having a major impact on patients’ outcomes. Myocardial injury (MI) occurs in the context of coronavirus infectious disease 2019 (COVID-19) and is associated with a higher risk of severe clinical outcome and mortality. COVID-19-related MI can have various clinical manifestations, of which the main ones are myocarditis, stress cardiomyopathy, acute coronary syndrome, and pulmonary embolism. The exact mechanisms of how MI occurs in these patients are not yet fully known. Direct injury, through direct viral myocardial invasion, and indirect injury, through interaction with angiotensin I converting enzyme 2, increased inflammation, and thrombocyte and endothelial dysfunction, could be involved in acute MI in patients with COVID-19. A better understanding of these multiple potential mechanisms may help to develop new targeted therapeutic strategies. The purpose of this review is to provide the current understanding of the potential mechanisms involved in MI induced by COVID-19 and to discuss the current progress in the therapeutic strategies.

Verified
Journal Article
Open access
PDF file
Teodora BarbalataTeodora Barbalata
Teodora Barbalata
ASAlina Scarlatescu
Alina Scarlatescu
GSGabriela Maria Sanda
Gabriela Maria Sanda
LTLaura Toma
Laura Toma
Camelia Sorina StancuCamelia Sorina Stancu
Camelia Sorina Stancu
Loredan Stefan NiculescuLoredan Stefan Niculescu
Loredan Stefan Niculescu
Myocardial infarction is one of the leading causes of death worldwide, despite numerous efforts to find efficient prognostic biomarkers and treatment targets. In the present study, we aimed to assess the potential of six microRNAs known to be involved in cardiovascular diseases, cell-free DNA (cfDNA), and mitochondrial DNA (mtDNA) circulating in plasma to be used as prognostic tools for the occurrence of unfavorable outcomes such as major adverse cardiovascular events (MACE) after acute ST-segment elevation myocardial infarction (STEMI). Fifty STEMI patients were enrolled and monitored for 6 months for the occurrence of MACE. Plasma was collected at three time points: upon admission to hospital (T0), at discharge from hospital (T1), and 6 months post-STEMI (T6). Plasma levels of miR-223-3p, miR-142-3p, miR-155-5p, miR-486-5p, miR-125a-5p, and miR-146a-5p, as well as of cfDNA and mtDNA, were measured by RT-qPCR. Results showed that the levels of all measured miRNAs, as well as of cfDNA and mtDNA, were the most increased at T1, compared to the other two time points. In the plasma of STEMI patients with MACE compared to those without MACE, we determined increased levels of miRNAs, cfDNA, and mtDNA at T1. Hence, we used the levels of all measured parameters at T1 for further statistical analysis. Statistical analysis demonstrated that all six miRNAs and cfDNA plus mtDNA levels, respectively, were associated with MACE. The minimal statistical model that could predict MACE in STEMI patients was the combination of mtDNA and miR-142-3p levels, as evidenced by ROC analysis (AUC = 0.97, p < 0.001). In conclusion, the increased plasma levels of mtDNA, along with miR-142-3p, could be used to predict unfavorable outcomes in STEMI patients.